EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Safety and clinical outcomes of pembrolizumab standard-interval dosing versus extended-interval dosing in patients with breast cancer

Alexis LeVee iD, Austin Kordic, Nora Ruel iD, Joanne Mortimer iD, Irene Kang iD, Heather McArthur, Melissa G Lechner iD, Karen Tsai iD

The Oncologist · 01.12.2025 · 30 (12)

DOI: 10.1093/oncolo/oyaf371 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, online erschienen am 07.11.2025. Verfasst von Alexis LeVee und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, UCLA Geffen School of Medicine, Los Angeles, CA, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Breast Neoplasms, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIDDK NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Extended-interval (EI) dosing of pembrolizumab (400 mg IV every 6 weeks) was approved across all solid tumors based on pharmacokinetic modeling and exposure-response analyses. Although EI dosing is more convenient for patients, whether the higher dose and extended dosing interval impacts immune-related adverse events (irAE) and clinical outcomes in patients with breast cancer is unknown.

Methods

In this retrospective cohort study, patients with breast cancer treated with pembrolizumab between 2017 and 2024 were included. Safety (irAE) and clinical outcomes including event-free survival (EFS), progression-free survival (PFS) and overall survival (OS) were compared between patients who received only standard-interval (SI) dosing (200 mg IV every 3 weeks) pembrolizumab and those who received ≥ 1 cycle of EI dosing.

Results

Of the 355 patients included, 59 (17%) received ≥ 1 cycle of EI and 296 (83%) received ≥ 1 cycle of only SI. Of those who received ≥ 1 cycle of pembrolizumab EI, 27 (45.8%) started with 200 mg, 7 (11.9%) started with 400 mg, 9 (15.2%) received only 400 mg, and 16 (27.1%) switched between dosing schedules. The majority (71%) of patients had early-stage disease, and 92% had triple-negative breast cancer. In patients with early-stage disease, rates of any-grade irAE were similar (p = 0.3), while grade 3 or higher irAE was lower in EI dosing versus SI (4% vs. 20%; p = 0.01). EFS and OS were similar between the two dosing regimens (p = 0.8 and p = 0.5, respectively). In patients with metastatic disease, any-grade irAE (p = 0.5), grade 3 or higher irAE (p = 0.1), PFS (p = 0.8), and OS (p = 0.5) were similar between the dosing regimens.

Conclusion

In this real-world study in which patients were often switched to EI dosing after initial SI therapy, safety and efficacy of EI dosing were maintained in patients with breast cancer. As more patients are treated with EI dosing, this data provides new evidence that switching to EI dosing is safe and effective, while improving medication burden for patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedBreast NeoplasmsAntineoplastic Agents, ImmunologicalHumansFemaleMiddle AgedRetrospective StudiesAgedAdultDrug Administration ScheduleAged, 80 and overTreatment Outcome

Stichwörter der Autor:innen

Immune-related adverse eventsbreast cancerextended-interval dosingimmunotherapypembrolizumab

Substanzen

pembrolizumabAntibodies, Monoclonal, HumanizedAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Division of Hematology and Oncology, UCLA Geffen School of Medicine, Los Angeles, CA, USA.
  • Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
  • Department of Biostatistics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
  • Division of Hematology and Oncology, UT Southwestern Medical Center, Dallas, TX, USA.
  • Division of Endocrinology, UCLA Geffen School of Medicine, Los Angeles, CA, USA.
  • Department of Diabetes, Endocrinology and Metabolism, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.

ORCID-Profile: Alexis LeVee, Nora Ruel, Joanne Mortimer, Irene Kang, Melissa G Lechner, Karen Tsai

Förderung

  • NIDDK NIH HHS
  • NIAID NIH HHS

Zitieren

APA

LeVee, A., Kordic, A., Ruel, N., Mortimer, J., Kang, I., McArthur, H., Lechner, M. G., & Tsai, K. (2025). Safety and clinical outcomes of pembrolizumab standard-interval dosing versus extended-interval dosing in patients with breast cancer. The Oncologist, 30(12). https://doi.org/10.1093/oncolo/oyaf371

Vancouver

LeVee A, Kordic A, Ruel N, Mortimer J, Kang I, McArthur H, et al. Safety and clinical outcomes of pembrolizumab standard-interval dosing versus extended-interval dosing in patients with breast cancer. The Oncologist. 2025;30(12). doi:10.1093/oncolo/oyaf371

BibTeX
@article{LeVee2025,
  author = {LeVee, Alexis and Kordic, Austin and Ruel, Nora and Mortimer, Joanne and Kang, Irene and McArthur, Heather and Lechner, Melissa G and Tsai, Karen},
  title = {Safety and clinical outcomes of pembrolizumab standard-interval dosing versus extended-interval dosing in patients with breast cancer},
  journal = {The Oncologist},
  year = {2025},
  volume = {30},
  number = {12},
  doi = {10.1093/oncolo/oyaf371}
}
Kostenlos starten →